AVTR vs. HALO: Avantor vs. Halozyme Therapeutics Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while HALO is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Profile Item	AVTR	HALO
Name	Avantor, Inc.	Halozyme Therapeutics Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.48 billion USD	11.81 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	March 16, 2004
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

HALO

GSPC

Avantor (AVTR) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Halozyme Therapeutics (HALO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Halozyme Therapeutics (HALO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Total Return (1Y)	36.41%	50.94%
Total Return (3Y, Annualized)	-5.02%	41.08%
Total Return (5Y, Annualized)	-16.62%	21.68%

Risk Profile

Drawdown History

AVTR

HALO

GSPC

Avantor (AVTR) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Halozyme Therapeutics (HALO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Volatility (1Y, Annualized)	43.39%	41.19%
Beta (5Y)	0.94	0.96
Max Drawdown (5Y)	-82.42%	-49.06%
Avg. Volume (3M)	8.56M	2.29M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and HALO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Sharpe Ratio (1Y)	0.74	1.13
Sortino Ratio (1Y)	1.17	1.78

Profitability

ROE (TTM)

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Avantor (AVTR) at 5.91%, which is closer to a typical peer reading.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Halozyme Therapeutics (HALO) at 59.84% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
ROE (TTM)	5.91%	216.38%
ROA (TTM)	2.83%	22.42%
Net Margin (TTM)	5.08%	26.93%
Operating Margin (TTM)	8.19%	59.84%
Gross Margin (TTM)	31.59%	77.74%

Growth

Revenue Growth

Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Halozyme Therapeutics (HALO) at -25.36% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Revenue Growth (YoY)	-3.41%	37.55%
Revenue Growth (3Y CAGR)	-4.46%	28.38%
EPS Growth (YoY)	-175.00%	-25.36%
EPS Growth (3Y CAGR)	--	21.14%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Avantor (AVTR) carries debt-to-equity ratio of 0.63 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): HALO does not report debt-to-equity ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Current Ratio (MRQ)	1.89	3.88
Debt / Equity (MRQ)	0.63	--
Net Debt / EBITDA	3.40	1.90

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Avantor (AVTR) at 30.94 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Avantor (AVTR) reports 1.80, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

Avantor (AVTR) vs. Halozyme Therapeutics (HALO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Halozyme Therapeutics (HALO)
Metric	AVTR	HALO
P/E Ratio (TTM)	30.94	25.91
P/S Ratio (TTM)	1.58	6.55
P/B Ratio (MRQ)	1.80	-213.67
Free Cash Flow Yield (TTM)	4.21%	3.48%